Drug intelligence / Profile preview

NT-88

Development stage: Phase 1
Lead developer: Guangzhou Manjing Biomedicine Technology

Overview

**NT-88** is an investigational pharmaceutical candidate developed by Guangzhou Manjing Biomedicine Technology for chronic heart failure with mildly reduced ejection fraction. It is being evaluated as an add-on to conventional therapy in a randomized, single-center, blinded clinical study. Public trial records refer to NT-88 as Zuozhu Daxi, but its molecular identity, dosage form, route of administration, and mechanism of action have not been publicly disclosed.

Other names: Zuozhu Daxi

Beyond the preview

Go deeper on NT-88.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NT-88.

Explore the full profile